Personalis (PSNL) Files Patent Infringement Lawsuit Against Foresight Diagnostics
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall Street rallies as Fed's Waller eases rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
Personalis Files Patent Infringement Lawsuit Against Foresight Diagnostics
August 2, 2022 4:10 PM EDTMENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it filed a lawsuit against Foresight Diagnostics Inc. for infringement of Personalis U.S. Patent Nos. 10,450,611, 11,299,783, and 11,384,394. These patents are part of Personalis intellectual property portfolio in the field of whole genome-enabled, tumor-informed molecular residual disease (MRD) testing.
Personalis patent portfolio protects its pioneering work in whole genome sequencing to identify mutations that indicate the continued presence or recurrence of cancer with part-per-million sensitivity. Personalis is seeking both injunctive relief and monetary damages... More
